-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30

Benzinga·12/22/2025 12:45:00
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and raises the price target from $28 to $30.